Compare KFRC & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFRC | ZVRA |
|---|---|---|
| Founded | 1962 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.3M | 472.9M |
| IPO Year | 1996 | 2015 |
| Metric | KFRC | ZVRA |
|---|---|---|
| Price | $26.72 | $9.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $38.50 | $21.71 |
| AVG Volume (30 Days) | 239.6K | ★ 597.6K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.97% | N/A |
| EPS Growth | N/A | ★ 34.27 |
| EPS | ★ 1.96 | 1.16 |
| Revenue | ★ $1,329,007,000.00 | $23,612,000.00 |
| Revenue This Year | $2.78 | $333.64 |
| Revenue Next Year | $4.32 | $44.19 |
| P/E Ratio | $13.63 | ★ $7.82 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.49 | $6.19 |
| 52 Week High | $52.50 | $13.16 |
| Indicator | KFRC | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 32.11 | 57.27 |
| Support Level | $24.49 | $8.61 |
| Resistance Level | $31.43 | $9.61 |
| Average True Range (ATR) | 1.69 | 0.31 |
| MACD | -0.65 | 0.04 |
| Stochastic Oscillator | 12.19 | 83.67 |
Kforce Inc is a solutions firm specializing in technology, finance and accounting, and other professional staffing services. The company operates two business segments: 1) In technology segment it provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. 2) In FA segment company offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting business and cost analysis; and taxation and treasury. The majority of revenue is earned through the technology segment.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.